SCHEMBL30759205

SCHEMBL30759205

C[C@@H](N)c1cc2cnccc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.46
NOD1 Q9Y239 3/20 0.41
CXCL8 P10145 2/20 0.41
HTR6 P50406 6/20 0.39
CA12 O43570 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
SRC P12931 1/20 0.37
RAPGEF4 Q8WZA2 1/20 0.36
ROCK2 O75116 3/20 0.36
ROCK1 Q13464 3/20 0.36
BRD4 O60885 1/20 0.36
GAA P10253 1/20 0.35
NOD2 Q9HC29 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30759190 1.00 RECQL (0.46) RECQLNOD1CXCL8HTR6CA12
SCHEMBL27140921 1.00 RECQL (0.46) RECQLNOD1CXCL8HTR6CA12
SCHEMBL27109421 1.00 RECQL (0.46) RECQLNOD1CXCL8HTR6CA12
SCHEMBL27108206 1.00 RECQL (0.46) RECQLNOD1CXCL8HTR6CA12
Hydrochloric Acid SCHEMBL27145489 0.99 RECQL (0.46) RECQLNOD1CXCL8HTR6CA12
Hydrochloric Acid SCHEMBL27144639 0.99 RECQL (0.46) RECQLNOD1CXCL8HTR6CA12
Hydrochloric Acid SCHEMBL27144637 0.99 RECQL (0.46) RECQLNOD1CXCL8HTR6CA12
Hydrochloric Acid SCHEMBL27145490 0.99 RECQL (0.46) RECQLNOD1CXCL8HTR6CA12
SCHEMBL27153056 0.89 LMNA (0.41) RECQLNOD1HTR6CA12CA2
SCHEMBL27153054 0.89 LMNA (0.41) RECQLNOD1HTR6CA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024044098-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-29 WO disclosed